ORIC Pharmaceuticals, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Jarvis is thinking

ORIC Pharmaceuticals, Inc. Share Price Today, Financials & AI Analysis — Stockinder

Income Statement

	2025-12-31	2024-12-31	2021-12-31	2020-12-31
Profit from core operations after subtracting the cost of revenue and operating expenses like R&D and marketing, but before interest and taxes.	-$143.00M	-$142.90M	-$78.87M	-$74.19M
The company's bottom-line profit after all expenses, interest, and taxes are subtracted.	-$129.47M	-$127.85M	-$78.72M	-$73.70M
Net income divided by the number of shares outstanding — profit attributable to each share.	$-1.47	$-1.83	$-2.07	$-3.36
Like basic EPS, but accounts for shares that could be created from stock options or convertible securities — a more conservative per-share profit figure.	$-1.47	$-1.83	–	–

Balance Sheet

	2025-12-31	2024-12-31	2021-12-31	2020-12-31
Cash and highly liquid short-term investments the company can access almost immediately.	$45.67M	$59.41M	$226.01M	$78.45M
Everything the company owns that has value — cash, property, inventory, investments, and more.	$408.89M	$274.14M	$298.64M	–
Everything the company owes — debt, unpaid bills, and other obligations.	$24.53M	$31.02M	$25.67M	–
What would be left for shareholders if the company sold all its assets and paid off all its debts — total assets minus total liabilities.	$384.36M	$243.12M	$272.98M	–

Cash Flow Statement

	2025-12-31	2024-12-31	2021-12-31	2020-12-31
Actual cash generated by the core business, as opposed to accounting profit, which can include non-cash items.	-$110.97M	-$112.66M	-$59.54M	-$45.27M
Cash spent on physical assets like property, equipment, and infrastructure to maintain or grow the business.	$712000	$1.19M	$939000	$667000
Cash left over after capital expenditures — money the company could use for dividends, buybacks, debt repayment, or reinvestment.	-$111.68M	-$113.85M	-$60.48M	-$45.94M